Although some MS therapeutics are attempting to tamp down the immune signals that lead to the loss of myelin, this study has tried another approach to repair myelin damage that has already happened.

Alison Hood, General Counsel Ms. Hood is an experienced general counsel in the biotech and pharma sector. She was previously VP & Head of Legal, International at Aimmune Therapeutics, a position she ...

Multiple sclerosis (MS) is a debilitating disease of the brain and spinal cord that impacts millions worldwide.

Cutia Therapeutics (HK:2487) has released an update. Cutia Therapeutics’ CEO, Ms. Zhang Lele, has further increased her stake ...

Seaport names Lauren White as CFO. Ms. White most recently served as CFO at ImmunoGen prior to its acquisition by AbbVie for ...

An accomplished biotech and healthcare executive, Ms. Deptula-Hicks most recently served as Chief Financial Officer of F-star Therapeutics Inc. (FSTX), which she took public on the NASDAQ in 2020, ...

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Prior to her work at Graphite Bio and LENZ Therapeutics, Ms. Drapkin served as CFO at Jounce Therapeutics, playing a key role in building the company’s financial infrastructure and securing $600 ...

In MS clinical trials, the incidence of infusion ... U.S. BRIUMVI Patient Support is a flexible program designed by TG Therapeutics to support U.S. patients through their treatment journey ...

Alison Hood, General Counsel Ms. Hood is an experienced general counsel in the biotech and pharma sector. She was previously VP & Head of Legal, International at Aimmune Therapeutics, a position she ...